As drug developers seek to produce more effective drugs, deeper insight into the patient journey from diagnosis to treatment is a priority. Taking non-small cell lung cancer (NSCLC), Purplelab and Genentech will explore how to use real-world data (RWD) to eliminate blind spots in the patient’s journey – Every stage from clinical development to market entry is informed of the life cycle of the drug.
The webinar will include Russ Cobb, executive of Purple Labs, chief marketing officer and webinar moderator, and Steve Emrick, senior vice president of Clinical Information Solutions and Health Nexus. Dr. Ben Freiberg also participated in the webinar, the main informatics system for Genentech’s GCS computing catalyst. Genentech is owned by Roche.
The conversation points that the webinar will introduce include:
- How do pharmaceutical companies use RWD for NSCLC patient journeys?
- What is the “typical” patient journey of NSCLC?
- Draw the subtle parts of the patient’s journey
- The value of social determinants of health data
- Addressing socioeconomic barriers that may hinder clinical trial participation
- Use RWD to improve clinical trial recruitment, clinical endpoints and inform market access strategies
To register for a webinar sponsored by Purplelab, which eliminates blind spots in the patient journey, scheduled on May 22 from 1-2 pm, please complete the following form:
